RESUMO
Objective:To investigate the safety and efficacy of nimotuzumab combined with IMRT radiotherapy in the treatment of elderly patients with locally advanced cervical cancer (LACC).Methods:A retrospective analysis was conducted for 34 elderly LACC patients treated with nimotuzumab combined with IMRT radiotherapy or concurrent chemoradiotherapy in the Zhangzhou Affiliated Hospital of Fujian Medical University from June 2020 to December 2021. The efficacy and side effects were evaluated one and two years after treatment.Results:Median follow-up time was 13.3 months (6.1-24.3 months). A total of 24 cases of complete response (CR) and eight cases of partial response (PR) were achieved after treatment, with an objective response rate (ORR) of 94.1% (32/34). The tumor diameters were (49.56 ± 19.22) mm before treatment and (19.61 ± 14.59) mm after treatment, with a tumor regression rate (TRR) of 59.22%.The 1- and 2- year progression-free survival (PFS) rates were 84.9% and 84.9%, overall survival (OS) rates 91.8% and 87.2%, respectively, disease-free survival (DFS) rates 91.8% and 87.2%, respectively, and the cancer-specific survival (CSS) rates 95.7% and 90.9%, respectively. The main adverse events included radiation enteritis, leukopenia, hypoproteinemia and anemia.Conclusions:Nimotuzumab combined with IMRT radiotherapy or concurrent chemoradiotherapy is safe and effective in the treatment of LACC.
RESUMO
Objective:To observe the clinical effect of Shufeng Xuanfei Zhike decoction on cough variant asthma.Methods:A total of 86 patients with cough variant asthma admitted to the Second People's Hospital of Yuyao from August 2016 to July 2017 were selected and divided into two groups according to the random digital table method, with 43 cases in each group.The control group was given conventional treatment, and the observation group was given Shufeng Xuanfei Zhike decoction combined with conventional treatment.The clinical efficacy, symptom score, inflammatory factors and adverse reactions were observed.Results:The total effective rate of the observation group was 95.35%(41/43), which was higher than 79.07%(34/43) of the control group, the difference was statistically significant(χ 2=5.108, P=0.024). The symptom scores of cough[(1.23±0.56)points], sputum[(0.66±0.27)points], nasal congestion[(0.64±0.30)points], shortness of breath[(0.55±0.18)points] and pharyngeal itch[(0.70±0.24)points] in the observation group were lower than those in the control group[(2.73±0.85)points, (1.18±0.52)point, (1.18±0.45)point, (1.02±0.47)points, (1.38±0.58)points], the differences were statistically significant( t=9.663, 5.820, 6.547, 6.124, 7.104, all P<0.05). After treatment, the levels of interleukin 4, interleukin 6, hypersensitive C-reactive protein and tumor necrosis factor alpha in the observation group were (5.26±1.68)ng/L, (8.35±1.00)ng/L, (2.08±0.21)mg/L, (0.75±0.22)ng/L, respectively, which were lower than those in the control group[(8.73±1.77)ng/L, (12.30±1.24)ng/L, (4.33±0.38)mg/L, (1.75±0.34)ng/L], and the differences were statistically significant( t=9.324, 16.260, 33.983, 16.192, all P<0.05). The level of interleukin 10 in the observation group [(29.94±8.88)ng/L] was higher than that in the control group[(22.66±8.37)ng/L]( t=3.912, P<0.05). No obvious adverse reactions were observed in both two groups. Conclusion:Shufeng Xuanfei Zhike decoction is safe and effective in the treatment of patients with cough variant asthma.
RESUMO
Exploring excellent new pullulanase genes, and enriching pullulanase theory are of great importance to realize the industrialization of pullulanase. Three genes, pulA, pulB and pulC, encoding pullulanases, were cloned from Bacillus cereus GXBC-3 by bioinformatics analyzing the open reading frame in Bacillus cereus, annotated as putative I and II pullulanases in the GenBank database. Characteristics of these recombinant enzymes were inducible intracellular expressed in Escherichia coli, the results showed PulA was typical II pullulanase. Recombinant PulA could hydrolyze alpha-1,4- and alpha-1,6-glycosidic bonds. Its specific activity was 32.89 U/mg with an optimum temperature of 40 degrees C and optimum pH 6.5 using pullulan as substrate. And for soluble starch substrate, its specific activity was 25.71 U/mg with an optimum temperature of 50 degrees C and optimum pH 7.0. PulB and PulC were I pullulanases and only hydrolyzed alpha-1,6-glycosidic bond. The specific activities, optimum temperature and optimum pH of PulB and PulC for pullulan substrate were 228.54 U/mg, 45 degrees C, 7.0 and 229.65 U/mg, 45 degrees C, 6.5, respectively.